291 related articles for article (PubMed ID: 33177525)
1. MEKK2 mediates aberrant ERK activation in neurofibromatosis type I.
Bok S; Shin DY; Yallowitz AR; Eiseman M; Cung M; Xu R; Li N; Sun J; Williams AL; Scott JE; Su B; Shim JH; Greenblatt MB
Nat Commun; 2020 Nov; 11(1):5704. PubMed ID: 33177525
[TBL] [Abstract][Full Text] [Related]
2. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.
Wang W; Nyman JS; Ono K; Stevenson DA; Yang X; Elefteriou F
Hum Mol Genet; 2011 Oct; 20(20):3910-24. PubMed ID: 21757497
[TBL] [Abstract][Full Text] [Related]
3. Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model.
Li H; Liu Y; Zhang Q; Jing Y; Chen S; Song Z; Yan J; Li Y; Wu X; Zhang X; Zhang Y; Case J; Yu M; Ingram DA; Yang FC
Pediatr Res; 2009 Jun; 65(6):613-8. PubMed ID: 19247213
[TBL] [Abstract][Full Text] [Related]
4. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
[TBL] [Abstract][Full Text] [Related]
5. Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.
Ahmad S; Johnson GL; Scott JE
Biochem Biophys Res Commun; 2015 Aug; 463(4):888-93. PubMed ID: 26056008
[TBL] [Abstract][Full Text] [Related]
6. JNK inhibitors increase osteogenesis in Nf1-deficient cells.
Sullivan K; El-Hoss J; Little DG; Schindeler A
Bone; 2011 Dec; 49(6):1311-6. PubMed ID: 21964323
[TBL] [Abstract][Full Text] [Related]
7. CHIP-dependent termination of MEKK2 regulates temporal ERK activation required for proper hyperosmotic response.
Maruyama T; Kadowaki H; Okamoto N; Nagai A; Naguro I; Matsuzawa A; Shibuya H; Tanaka K; Murata S; Takeda K; Nishitoh H; Ichijo H
EMBO J; 2010 Aug; 29(15):2501-14. PubMed ID: 20588253
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis type 1 alternative splicing is a key regulator of Ras/ERK signaling and learning behaviors in mice.
Nguyen HT; Hinman MN; Guo X; Sharma A; Arakawa H; Luo G; Lou H
Hum Mol Genet; 2017 Oct; 26(19):3797-3807. PubMed ID: 28934393
[TBL] [Abstract][Full Text] [Related]
9. Neurofibromin regulation of ERK signaling modulates GABA release and learning.
Cui Y; Costa RM; Murphy GG; Elgersma Y; Zhu Y; Gutmann DH; Parada LF; Mody I; Silva AJ
Cell; 2008 Oct; 135(3):549-60. PubMed ID: 18984165
[TBL] [Abstract][Full Text] [Related]
10. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.
de la Croix Ndong J; Stevens DM; Vignaux G; Uppuganti S; Perrien DS; Yang X; Nyman JS; Harth E; Elefteriou F
J Bone Miner Res; 2015 Jan; 30(1):55-63. PubMed ID: 25043591
[TBL] [Abstract][Full Text] [Related]
11. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE
BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841
[TBL] [Abstract][Full Text] [Related]
12. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1.
Yan J; Chen S; Zhang Y; Li X; Li Y; Wu X; Yuan J; Robling AG; Kapur R; Chan RJ; Yang FC
Hum Mol Genet; 2008 Apr; 17(7):936-48. PubMed ID: 18089636
[TBL] [Abstract][Full Text] [Related]
13. Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.
de la Croix Ndong J; Makowski AJ; Uppuganti S; Vignaux G; Ono K; Perrien DS; Joubert S; Baglio SR; Granchi D; Stevenson DA; Rios JJ; Nyman JS; Elefteriou F
Nat Med; 2014 Aug; 20(8):904-10. PubMed ID: 24997609
[TBL] [Abstract][Full Text] [Related]
14. Identification of MEKK2/3 serine phosphorylation site targeted by the Toll-like receptor and stress pathways.
Zhang D; Facchinetti V; Wang X; Huang Q; Qin J; Su B
EMBO J; 2006 Jan; 25(1):97-107. PubMed ID: 16362041
[TBL] [Abstract][Full Text] [Related]
15. Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.
Chohan H; Esfandiarei M; Arman D; Van Raamsdonk CD; van Breemen C; Friedman JM; Jett KA
PLoS One; 2018; 13(12):e0208835. PubMed ID: 30571760
[TBL] [Abstract][Full Text] [Related]
16. GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice.
Park JI; Powers JF; Tischler AS; Strock CJ; Ball DW; Nelkin BD
Exp Cell Res; 2005 Feb; 303(1):79-88. PubMed ID: 15572029
[TBL] [Abstract][Full Text] [Related]
17. MEKK2 mediates an alternative β-catenin pathway that promotes bone formation.
Greenblatt MB; Shin DY; Oh H; Lee KY; Zhai B; Gygi SP; Lotinun S; Baron R; Liu D; Su B; Glimcher LH; Shim JH
Proc Natl Acad Sci U S A; 2016 Mar; 113(9):E1226-35. PubMed ID: 26884171
[TBL] [Abstract][Full Text] [Related]
18. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice.
Schindeler A; Ramachandran M; Godfrey C; Morse A; McDonald M; Mikulec K; Little DG
J Orthop Res; 2008 Jan; 26(1):65-74. PubMed ID: 17787010
[TBL] [Abstract][Full Text] [Related]
19. NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development.
Sanchez-Ortiz E; Cho W; Nazarenko I; Mo W; Chen J; Parada LF
Genes Dev; 2014 Nov; 28(21):2407-20. PubMed ID: 25367036
[TBL] [Abstract][Full Text] [Related]
20. Dimerization through the catalytic domain is essential for MEKK2 activation.
Cheng J; Yu L; Zhang D; Huang Q; Spencer D; Su B
J Biol Chem; 2005 Apr; 280(14):13477-82. PubMed ID: 15695508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]